We have generated a xenogeneic vaccine against human carcinoembryonic antigen (hCEACAM-5 or commonly hCEA) using as immunogen rhesus CEA (rhCEA). RhCEA cDNA was codon-usage optimized (rhCEAopt) and delivered by sequential DNA electro-gene-transfer (DNA-EGT) and adenoviral (Ad) vector. RhCEAopt was capable to break tolerance to CEA in hCEA transgenic mice and immune responses were detected against epitopes distributed over the entire length of the protein. Xenovaccination with rhCEA resulted in the activation of CD4+ T-cell responses in addition to self-reactive CD8+ T-cells, the development of high-titer antibodies against hCEA, and significant antitumor effects upon challenge with hCEA+ tumor cells. The superior activity of rhCEAopt compared with hCEAopt was confirmed in hCEA/HHD double-transgenic mice, where potent CD8+ T-cell responses against specific human HLA A*0201 hCEA epitopes were detected. Our data show that xenogeneic gene-based vaccination with rhCEA is a viable approach to break tolerance against CEA, thus suggesting further development in the clinical setting.
Get full access to this article
View all access options for this article.
References
1.
GuoC, ManjiliMH, SubjeckJR, et al.Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res, 2013; 119:421–475.
2.
CouliePG, Van den EyndeBJ, van der BruggenP, et al.Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer, 2014; 14:135–146.
3.
LohrJ, KnoechelB, NagabhushanamV, et al.T-cell tolerance and autoimmunity to systemic and tissue-restricted self-antigens. Immunol Rev, 2005; 204:116–127.
4.
CavalloF, AurisicchioL, ManciniR, et al.Xenogene vaccination in the therapy of cancer. Expert Opin Biol Ther, 2014; 14:1427–1442.
5.
OverwijkWW, TsungA, IrvineKR, et al.gp100/pmel 17 is a murine tumor rejection antigen: induction of “self”-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med, 1998; 188:277–286.
6.
GoldJS, FerroneCR, Guevara-PatiñoJA, et al.A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J Immunol, 2003; 170:5188–5194.
7.
ZhangW, LiuJ, WuY, et al.Immunotherapy of hepatocellular carcinoma with a vaccine based on xenogeneic homologous alpha fetoprotein in mice. Biochem Biophys Res Commun, 2008; 376:10–14.
8.
SuJM, WeiYQ, TianL, et al.Active immunogene therapy of cancer with vaccine on the basis of chicken homologous matrix metalloproteinase-2. Cancer Res, 2003; 63:600–607.
9.
BergmanPJ, Camps-PalauMA, McKnightJA, et al.Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine, 2006; 24:4582–4585.
10.
SarobeP, HuarteE, LasarteJJ, et al.Carcinoembryonic antigen as a target to induce anti-tumor immune responses. Curr Cancer Drug Targets, 2004; 4:443–454.
SandersDS, KerrMA. Lewis blood group and CEA related antigens; coexpressed cell-cell adhesion molecules with roles in the biological progression and dissemination of tumours. Mol Pathol, 1999; 52:174–178.
13.
BosR, van DuikerenS, van HallT, et al.Expression of a natural tumor antigen by thymic epithelial cells impairs the tumor-protective CD4+ T-cell repertoire. Cancer Res, 2005; 65:6443–6449.
14.
HöchstB, SchildbergFA, BöttcherJ, et al.Liver sinusoidal endothelial cells contribute to CD8 T cell tolerance toward circulating carcinoembryonic antigen in mice. Hepatology, 2012; 56:1924–1933.
15.
AurisicchioL, CilibertoG. Genetic cancer vaccines: current status and perspectives. Expert Opin Biol Ther, 2012; 12:1043–1058.
16.
AurisicchioL, ManciniR, CilibertoG. Cancer vaccination by electro-gene-transfer. Expert Rev Vaccines, 2013; 12:1127–1137.
17.
JohnsonJA, BarouchDH, BadenLR. Nonreplicating vectors in HIV vaccines. Curr Opin HIV AIDS, 2013; 8:412–420.
18.
AurisicchioL, PeruzziD, KooG, et al.Immunogenicity and therapeutic efficacy of a dual-component genetic cancer vaccine cotargeting carcinoembryonic antigen and HER2/neu in preclinical models. Hum Gene Ther, 2014; 25:121–131.
19.
AurisicchioL, MennuniC, GiannettiP, et al.Immunogenicity and safety of a DNA prime/adenovirus boost vaccine against rhesus CEA in nonhuman primates. Int J Cancer, 2007; 120:2290–2300.
20.
MennuniC, CalvarusoF, FacciabeneA, et al.Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA. Int J Cancer, 2005; 117:444–455.
21.
ClarkeP, MannJ, SimpsonJF, et al.Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy. Cancer Res, 1998; 58:1469–1477.
22.
FiratH, Garcia-PonsF, TourdotS, et al.H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies. Eur J Immunol, 1999; 29:3112–3221.
23.
FacciabeneA, AurisicchioL, EliaL, et al.Vectors encoding carcinoembryonic antigen fused to the B subunit of heat-labile enterotoxin elicit antigen-specific immune responses and antitumor effects. Vaccine, 2007; 26:47–58.
24.
ConfortiA, PeruzziD, GiannettiP, et al.A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses. J Immunother, 2009; 32:744–754.
25.
GiannettiP, FacciabeneA, La MonicaN, et al.Individual mouse analysis of the cellular immune response to tumor antigens in peripheral blood by intracellular staining for cytokines. J Immunol Methods, 2006; 316:84–96.
26.
FacciabeneA, AurisicchioL, EliaL, et al.DNA and adenoviral vectors encoding carcinoembryonic antigen fused to immunoenhancing sequences augment antigen-specific immune response and confer tumor protection. Hum Gene Ther, 2006; 17:81–92.
27.
LuJ, HigashimotoY, AppellaE, et al.Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses. J Immunol, 2004; 172:4575–4582.
28.
CiprianiB, FridmanA, BendtsenC, et al.Therapeutic vaccination halts disease progression in BALB-neuT mice: the amplitude of elicited immune response is predictive of vaccine efficacy. Hum Gene Ther, 2008; 19:670–680.
29.
MennuniC, UgelS, MoriF, et al.Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer. Cancer Res, 2008; 68:9865–9874.
30.
SaadeF, PetrovskyN. Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines, 2012; 11:189–209.
31.
GiuntoliRL, LuJ, KobayashiH, et al.Direct costimulation of tumor-reactive CTL by helper T cells potentiate their proliferation, survival, and effector function. Clin Cancer Res, 2002; 8:922–931.
32.
MincheffM, ZoubakS, MakogonenkoY. Immune responses against PSMA after gene-based vaccination for immunotherapy-A: results from immunizations in animals. Cancer Gene Ther, 2006; 13:436–444
33.
AurisicchioL, FridmanA, BagchiA, et al.A novel minigene scaffold for therapeutic cancer vaccines. Oncoimmunology, 2014; 3:e27529.
34.
KantoffPW, HiganoCS, ShoreND, et al.Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med, 2010; 363:411–422.
35.
Couzin-FrankelJ. Breakthrough of the year 2013. Cancer immunotherapy. Science, 2013; 342:1432–1433.
36.
GameiroSR, JammehML, HodgeJW. Cancer vaccines targeting carcinoembryonic antigen: state-of-the-art and future promise. Expert Rev Vaccines, 2013; 12:617–629.
37.
XuM, KallinterisNL, von HofeE. CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines. Vaccine, 2012; 30:2805–2810.
38.
StevensonFK, OttensmeierCH, JohnsonP, et al.DNA vaccines to attack cancer. Proc Natl Acad Sci USA, 2004; 101Suppl 2:14646–14652.
39.
QuaglinoE, MastiniC, AmiciA, et al.A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins. Cancer Res, 2010; 70:2604–2612.
40.
IeroM, SquarcinaP, RomeroP, et al.Low TCR avidity and lack of tumor cell recognition in CD8(+) T cells primed with the CEA-analogue CAP1-6D peptide. Cancer Immunol Immunother, 2007; 56:1979–1991.
41.
SteitzJ, BrückJ, SteinbrinkK, et al.Genetic immunization of mice with human tyrosinase-related protein 2: implications for the immunotherapy of melanoma. Int J Cancer, 2000; 86:89–94.
42.
KianizadK, MarshallLA, GrinshteinN, et al.Elevated frequencies of self-reactive CD8+ T cells following immunization with a xenoantigen are due to the presence of a heteroclitic CD4+ T-cell helper epitope. Cancer Res, 2007; 67:6459–6467.
43.
BarnettTR, DrakeL, PickleW2nd. Human biliary glycoprotein gene: characterization of a family of novel alternatively spliced RNAs and their expressed proteins. Mol Cell Biol, 1993; 12:1273–1282.
44.
DiazCM, ChiapporiA, AurisicchioL, et al.Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors. J Transl Med, 2013; 8:11–62.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
